Efficacy and safety of asciminib in heavily pretreated patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP) with sensitivity to tyrosine kinase inhibitors (TKIs) Meeting Abstract
| Authors: | Hughes, T.; Mauro, M.; Kim, D. W.; Cortes, J.; Réa, D.; Minami, H.; Breccia, M.; DeAngelo, D.; Hochhaus, A.; Goh, Y. T.; le Coutre, P.; Lang, F.; Cacciatore, S.; Aimone, P.; Stenson, L.; Polydoros, F.; Talpaz, M. |
| Abstract Title: | Efficacy and safety of asciminib in heavily pretreated patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP) with sensitivity to tyrosine kinase inhibitors (TKIs) |
| Meeting Title: | 8th Annual Meeting of the Society of Hematologic Oncology (SOHO) |
| Keywords: | cml; chronic myeloid leukemia; tyrosine kinase inhibitor; refractory; relapsed; discontinuation; asciminib |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 20 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2020 Sep 9-12 |
| Meeting Location: | Houston, TX |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2020-09-01 |
| Start Page: | S235 |
| Language: | English |
| ACCESSION: | WOS:000564055100189 |
| PROVIDER: | wos |
| DOI: | 10.1016/S2152-2650(20)30816-8 |
| Notes: | Meeting Abstract: CML-121 -- Due to COVID-19 pandemic, the conference was held virtually -- Source: Wos |
